Case Report: Lenvatinib plus osimertinib treated a metastatic hilar cholangiocarcinoma patient harboring EGFR mutation
Background Hilar cholangiocarcinoma (hCCA) is an aggressive malignancy with limited therapeutic options and poor prognosis, particularly in patients with unresectable or metastatic disease. Although immune checkpoint inhibitors and targeted therapies have improved outcomes, resistance remains a major challenge. Here, w...